Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 13/20 | 1.00 |
| ▸ | RIPK1 | Q13546 | 8/20 | 1.00 |
| ▸ | KDR | P35968 | 6/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | IKBKB | O14920 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | PDGFA | P04085 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 1/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 1/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | FGFR3 | P22607 | 1/20 | 1.00 |
| ▸ | CDK2 | P24941 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 1/20 | 1.00 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 1.00 |
| ▸ | TEK | Q02763 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22567120 | 0.94 | BRAF (0.90) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL29525367 | 0.91 | BRAF (0.83) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL22275546 | 0.90 | RIPK1 (0.82) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL823546 | 0.89 | BRAF (1.00) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL28496454 | 0.89 | RIPK1 (0.81) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL823638 | 0.89 | RIPK1 (0.81) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL29525771 | 0.88 | BRAF (0.81) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL826332 | 0.88 | BRAF (0.80) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL823554 | 0.88 | RIPK1 (0.78) | BRAFRIPK1KDRRIPK3CHEK1 | |
| SCHEMBL25412537 | 0.85 | RIPK1 (1.00) | BRAFRIPK1KDRRIPK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 701 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735598-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | Christiana Care Gene Editing Institute, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| US-20250179584-A1 | PRECISION THERAPY FOR THE TREATMENT OF CANCER | NOVARTIS AG (CH) | 2025-06-05 | — | — | US | claimed |
| US-20250108055-A1 | COMBINATION THERAPIES | MIRATI THERAPEUTICS INC (US) | 2025-04-03 | — | — | US | claimed |
| WO-2025027223-A1 | DYRK2 INHIBITORS FOR TREATING TUMOURS WITH THE HYPERACTIVE MAPK/ERK PATHWAY | Universidad de Córdoba (ES) | 2025-02-06 | — | — | WO | claimed |
| EP-4486920-A2 | PRECISION THERAPY FOR THE TREATMENT OF CANCER | Novartis AG (CH) | 2025-01-08 | — | — | EP | claimed |
| US-20250001010-A1 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | CHRISTIANA CARE GENE EDITING INSTITUTE, INC. (US) | 2025-01-02 | — | — | US | claimed |
| WO-2025007140-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | CHRISTIANA CARE GENE EDITING INSTITUTE, INC. (US) | 2025-01-02 | — | — | WO | claimed |
| WO-2024256607-A1 | STANDARDISING PLURIPOTENT STEM CELLS | UNITED KINGDOM RESEARCH AND INNOVATION (GB) | 2024-12-19 | — | — | WO | claimed |
| WO-2017165491-A1 | USE OF A PD-1 ANTAGONIST AND A RAF INHIBITOR IN THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-09-28 | — | — | WO | claimed |
| EP-2358689-B9 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2016-08-03 | — | — | EP | claimed |
| EP-2358689-B1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | claimed |
| US-20150126533-A1 | ADMINISTRATION OF A RAF INHIBITOR AND A MEK INHIBITOR IN THE TREATMENT OF MELANOMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | claimed |
| US-8497274-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-07-30 | — | — | US | claimed |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-23 | — | — | US | claimed |
| US-8143258-B2 | Benzothiazole compounds useful for Raf inhibition | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-27 | — | — | US | claimed |
| EP-2358689-A1 | Benzothiazole derivatives as anticancer agents | Takeda Pharmaceutical Company Limited (JP) | 2011-08-24 | — | — | EP | claimed |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | claimed |
| WO-2010064722-A1 | BENZOTHIAZOLE DERIVATIVES AS ANTICANCER AGENTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-10 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250108055-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | BRAF 4/4885RIPK1 2244/4885KDR 1786/4885 |
| US-20250179584-A1 | PRECISION THERAPY FOR THE TREATMENT OF CANCER | KRAS, NRAS, BRAF | BRAF 3/4885RIPK1 1633/4885KDR 1061/4885 |
| US-20150126533-A1 | ADMINISTRATION OF A RAF INHIBITOR AND A MEK INHIBITOR IN THE TREATMENT OF MELANOMA | BRAF, RAF1, ARAF | BRAF 1/4885RIPK1 127/4885KDR 645/4885 |
| US-20120214855-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885RIPK1 736/4885KDR 1130/4885 |
| US-20100216810-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885RIPK1 736/4885KDR 1130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.